CN111712263B - 基于美登木素生物碱的药物递送系统 - Google Patents

基于美登木素生物碱的药物递送系统 Download PDF

Info

Publication number
CN111712263B
CN111712263B CN201880088076.0A CN201880088076A CN111712263B CN 111712263 B CN111712263 B CN 111712263B CN 201880088076 A CN201880088076 A CN 201880088076A CN 111712263 B CN111712263 B CN 111712263B
Authority
CN
China
Prior art keywords
cancer
carcinoma
compound
pharmaceutically acceptable
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880088076.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN111712263A (zh
Inventor
F·克拉茨
K·阿布阿贾伊
A·瓦尔内克
F·I·诺尔曼
S·D·克斯特
J·加西亚费尔南德斯
L·帕斯
H-K·瓦尔特
J·P·马格努松
S·切尔切亚
P·佩雷斯加兰
F·梅达
S·J·道姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LadRx Corp
Original Assignee
Radex Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Radex Co filed Critical Radex Co
Publication of CN111712263A publication Critical patent/CN111712263A/zh
Application granted granted Critical
Publication of CN111712263B publication Critical patent/CN111712263B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880088076.0A 2017-11-30 2018-11-30 基于美登木素生物碱的药物递送系统 Active CN111712263B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762593184P 2017-11-30 2017-11-30
US62/593,184 2017-11-30
PCT/US2018/063380 WO2019108975A1 (en) 2017-11-30 2018-11-30 Maytansinoid-based drug delivery systems

Publications (2)

Publication Number Publication Date
CN111712263A CN111712263A (zh) 2020-09-25
CN111712263B true CN111712263B (zh) 2024-12-17

Family

ID=64744962

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880088076.0A Active CN111712263B (zh) 2017-11-30 2018-11-30 基于美登木素生物碱的药物递送系统

Country Status (11)

Country Link
US (2) US11572373B2 (https=)
EP (1) EP3717018A1 (https=)
JP (2) JP7442821B2 (https=)
KR (1) KR20200117988A (https=)
CN (1) CN111712263B (https=)
AU (1) AU2018375788A1 (https=)
BR (1) BR112020010989A2 (https=)
CA (1) CA3083985A1 (https=)
IL (2) IL274920B2 (https=)
MX (1) MX2020005472A (https=)
WO (1) WO2019108975A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6948708B2 (ja) 2015-06-19 2021-10-13 センチュリオン バイオファーマ コーポレイション 薬物制御放出のための送達系
EP4344747A3 (en) 2017-11-30 2024-07-03 LadRx Corporation Albumin-binding prodrugs of auristatin e derivatives
CN110227164B (zh) 2018-03-06 2021-11-23 江苏吉贝尔药业股份有限公司 含酮羰基的疏水性抗肿瘤药物及其缀合物、含有缀合物的纳米制剂及其制备方法及应用
JP2024546948A (ja) 2021-12-15 2024-12-26 ジ アドミニストレイターズ オブ ザ チューレン エデュケイショナル ファンド コンジュゲート、それらの組成物、及びそれらの関連する方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1183050A2 (de) * 1999-06-09 2002-03-06 KTB Tumorforschungsgesellschaft mbH Verfahren zur herstellung einer injizierbaren arzneimittelzubereitung
CN105849086A (zh) * 2012-11-24 2016-08-10 杭州多禧生物科技有限公司 亲水性链接体及其在药物分子和细胞结合分子共轭反应上的应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4125704A (en) 1977-09-14 1978-11-14 Sri International Phenyl-substituted rubidazone analogs
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4699880A (en) 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
US4966999A (en) 1988-06-07 1990-10-30 Cytogen Corporation Radiohalogenated compounds for site specific labeling
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
CA2115811A1 (en) 1993-02-17 1994-08-18 Claus Krebber A method for in vivo selection of ligand-binding proteins
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
NZ547370A (en) 2003-12-04 2010-09-30 Amr Technology Inc Vinca derivatives
CN101743020A (zh) 2007-05-16 2010-06-16 Ktb肿瘤研究有限责任公司 低粘度蒽环制剂
EP2289558A1 (en) 2009-08-25 2011-03-02 KTB Tumorforschungsgesellschaft mbH Bisphosphonate-prodrugs
WO2012145112A2 (en) * 2011-04-18 2012-10-26 Immunogen, Inc. Novel maytansinoid derivatives with sulfoxide linker
CN104185477B (zh) 2011-11-17 2017-05-24 辉瑞公司 细胞毒性肽及其抗体‑药物缀合物
EP2630971B8 (en) 2012-02-21 2017-12-13 Vergell Medical S.A. Combinations of albumin-based drug delivery systems
CN104688740A (zh) 2012-12-21 2015-06-10 百奥泰生物科技(广州)有限公司 类美登素衍生物及其制备方法和用途
US20140221429A1 (en) 2013-02-04 2014-08-07 Saud Ibrahim Al-Resayes Heterocyclic schiff's bases as novel and new antiglycation agents
EP3566750A3 (en) * 2013-02-28 2020-04-08 ImmunoGen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
BR112017020149A8 (pt) * 2015-03-27 2023-05-02 Regeneron Pharma Derivados de maitansinoide, conjugados dos mesmos e métodos de uso
WO2016205378A1 (en) 2015-06-15 2016-12-22 Abbott Diabetes Care Inc. Stabilized lactate responsive enzymes, electrodes and sensors, and methods for making and using the same
JP6948708B2 (ja) * 2015-06-19 2021-10-13 センチュリオン バイオファーマ コーポレイション 薬物制御放出のための送達系
EP4344747A3 (en) 2017-11-30 2024-07-03 LadRx Corporation Albumin-binding prodrugs of auristatin e derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1183050A2 (de) * 1999-06-09 2002-03-06 KTB Tumorforschungsgesellschaft mbH Verfahren zur herstellung einer injizierbaren arzneimittelzubereitung
CN105849086A (zh) * 2012-11-24 2016-08-10 杭州多禧生物科技有限公司 亲水性链接体及其在药物分子和细胞结合分子共轭反应上的应用

Also Published As

Publication number Publication date
EP3717018A1 (en) 2020-10-07
IL274920B1 (en) 2023-09-01
US20200385403A1 (en) 2020-12-10
RU2020121456A (ru) 2021-12-30
CN111712263A (zh) 2020-09-25
AU2018375788A1 (en) 2020-07-09
JP2021505551A (ja) 2021-02-18
JP7442821B2 (ja) 2024-03-05
BR112020010989A2 (pt) 2020-11-17
CA3083985A1 (en) 2019-06-06
WO2019108975A1 (en) 2019-06-06
US11572373B2 (en) 2023-02-07
JP2023164604A (ja) 2023-11-10
IL274920A (en) 2020-07-30
US20230391794A1 (en) 2023-12-07
MX2020005472A (es) 2020-11-11
KR20200117988A (ko) 2020-10-14
IL274920B2 (en) 2024-01-01
RU2020121456A3 (https=) 2022-04-13
IL305268A (en) 2023-10-01

Similar Documents

Publication Publication Date Title
CN111712511B (zh) 澳瑞他汀e衍生物的白蛋白结合产物
CN111712263B (zh) 基于美登木素生物碱的药物递送系统
US11384104B2 (en) Delivery systems for controlled drug release
RU2783076C2 (ru) Системы доставки лекарств на основе майтанзиноида
RU2795101C2 (ru) Альбумин-связывающие пролекарства на основе производных ауристатина е
CA3083983C (en) Albumin-binding prodrugs of auristatin e derivatives
HK40110772A (en) Albumin-binding prodrugs of auristatin e derivatives
HK40069235A (en) Delivery systems for controlled drug release
HK40040808A (en) Albumin-binding prodrugs of auristatin e derivatives
HK40040808B (en) Albumin-binding prodrugs of auristatin e derivatives
BR112017027445B1 (pt) Compostos, composição farmacêutica e uso dos mesmos para tratar um câncer, uma doença viral, uma doença autoimune, uma doença inflamatória aguda ou crônica e uma doença causada por bactérias, fungos, ou outros micro-organismos

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Country or region after: U.S.A.

Address after: California, USA

Applicant after: Radex Co.

Address before: California, USA

Applicant before: CYTRX Corp.

Country or region before: U.S.A.

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20240604

Address after: California, USA

Applicant after: CYTRX Corp.

Country or region after: U.S.A.

Address before: California, USA

Applicant before: Sentorian Biopharmaceutical Co.

Country or region before: U.S.A.

GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment

Free format text: NEW EXPIRY DATE: 20390120

TG01 Patent term adjustment